PERGONAL Drug Profile

Summary for Tradename: PERGONAL

High Confidence Patents:	0
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for PERGONAL Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for PERGONAL Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for PERGONAL Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Emd Serono, Inc.	PERGONAL	menotropins	For Injection	017646		2036-12-20	Patent claims search
Emd Serono, Inc.	PERGONAL	menotropins	For Injection	017646		2038-12-19	Patent claims search
Emd Serono, Inc.	PERGONAL	menotropins	For Injection	017646		2037-11-08	Patent claims search
Emd Serono, Inc.	PERGONAL	menotropins	For Injection	017646		2036-10-07	Patent claims search

PERGONAL: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Pergonal, an injectable gonadotropin therapy, has a long-standing presence in the reproductive health market. Its efficacy in stimulating ovulation in women and sperm production in men under specific hormonal deficiencies has secured a niche but consistent demand. The drug's market dynamics are influenced by evolving treatment guidelines, competition from newer modalities, and patent expiries leading to generic penetration. Its financial trajectory reflects these factors, with revenue streams largely stabilized but subject to pricing pressures and market share shifts.

What is the Current Market Position of Pergonal?

Pergonal is primarily indicated for the treatment of infertility in women who have not responded to other treatments and in men with primary hypogonadotropic hypogonadism. Its active pharmaceutical ingredients are menotropins, a mixture of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), extracted from the urine of postmenopausal women.

The market for Pergonal is characterized by several key aspects:

• Established but Mature Market: Pergonal has been available for decades. This longevity has led to a well-understood efficacy profile and established treatment protocols. However, it also indicates a mature market segment with limited organic growth potential from new patient acquisition.
• Niche Application: While effective, Pergonal is prescribed for specific infertility diagnoses. It is not a broad-spectrum fertility treatment. This specificity limits its overall market size compared to more widely applicable fertility drugs.
• Competition: The fertility market has seen significant advancements. Newer recombinant FSH (rFSH) products, such as Gonal-f and Puregon, offer more standardized hormone ratios and potentially greater ease of administration and monitoring. These have captured market share, particularly in developed markets where cost is less of a primary barrier and where newer technologies are favored.
• Generic Availability: The patent protection for the original Pergonal product has long expired. This has allowed for the introduction of generic versions, which typically compete on price. The presence of generics exerts downward pressure on the brand-name drug's pricing and market share.
• Geographic Distribution: Pergonal's market penetration varies geographically. While its use may be more prevalent in regions with greater price sensitivity or where access to newer biotechnologies is limited, its market share in highly developed economies has likely diminished due to the aforementioned competition.
• Regulatory Landscape: Fertility treatments are subject to stringent regulatory oversight. Changes in prescribing guidelines, drug safety alerts, or new efficacy data can impact market dynamics.

As of recent market analyses, Pergonal occupies a specific segment within the gonadotropin market, primarily serving as a cost-effective option for certain patient populations or in regions where advanced therapies are less accessible.

What are the Key Patents and Intellectual Property Considerations for Pergonal?

The original patent landscape for Pergonal, as a product derived from urinary gonadotropins, is largely expired. The primary patents would have covered its composition of matter, manufacturing processes, and therapeutic uses.

• Composition of Matter Patents: The fundamental patents covering the specific hormonal composition of Pergonal have long expired. This was the earliest form of intellectual property protection.
• Process Patents: Patents related to the methods of extracting, purifying, and formulating menotropins from human urine would have also been central. These processes have likely been refined over time, and any newer process patents would have had limited lifespans.
• Formulation Patents: Patents covering specific dosage forms, delivery systems, or stabilization techniques for Pergonal could have provided extended protection. However, the primary formulation of Pergonal is a well-established injectable solution.
• Use Patents: Patents for specific therapeutic uses or indications within infertility treatment could have existed. These would have been subject to patent term extensions based on regulatory review periods.
• Generic Entry: The expiration of key patents, particularly composition and core process patents, paved the way for generic manufacturers. This is a critical factor in Pergonal's current market dynamics. The ability of generic competitors to produce bioequivalent versions at lower costs significantly impacts the pricing and market share of the originator product.
• Exclusivity Periods: Regulatory exclusivities, such as data exclusivity or market exclusivity granted by regulatory agencies like the FDA or EMA, would have applied for a period after initial approval, independent of patent protection. However, these are also time-limited.

Current intellectual property considerations for Pergonal are primarily focused on the manufacturing and quality control of generic versions to ensure bioequivalence and therapeutic equivalence to the originator product. The originator company may retain trademarks and brand recognition. Any new IP would likely pertain to novel delivery systems or combination therapies, which do not appear to be a primary focus for Pergonal given its established profile.

How Has Pergonal's Clinical Efficacy and Safety Profile Evolved?

Pergonal's clinical profile has been established over several decades of use. Its efficacy and safety are well-documented, though advancements in comparative studies and newer therapies provide a modern context.

• Efficacy: Pergonal effectively stimulates follicular development in women and spermatogenesis in men when administered under appropriate medical supervision.
  • In Women: It is indicated for ovulation induction in women with certain forms of anovulation, particularly when pituitary function is intact but ovarian function is impaired. Clinical trials and real-world data have consistently demonstrated its ability to induce the development of multiple follicles.
  • In Men: It is used to stimulate testicular steroidogenesis and spermatogenesis in men with hypogonadotropic hypogonadism, often in conjunction with human chorionic gonadotropin (hCG).
• Safety Profile: Like all gonadotropin therapies, Pergonal carries potential risks and side effects.
  • Ovarian Hyperstimulation Syndrome (OHSS): This is a serious complication characterized by rapid fluid accumulation, electrolyte imbalances, and potential organ impairment. The incidence and severity of OHSS are dose-dependent and influenced by individual patient factors. Protocols are in place to monitor and manage this risk.
  • Multiple Pregnancies: The stimulation of multiple follicles increases the likelihood of multiple births (twins, triplets, or more), which are associated with higher maternal and neonatal risks.
  • Ectopic Pregnancy: There is a slightly increased risk of ectopic pregnancy with assisted reproductive technologies that utilize gonadotropins.
  • Other Side Effects: Common side effects include injection site reactions (pain, redness, swelling), headache, nausea, and abdominal discomfort.
• Comparison to Newer Therapies:
  • Recombinant FSH (rFSH): Newer rFSH products are produced using recombinant DNA technology, offering a more purified and consistent FSH preparation. While Pergonal's FSH and LH content is standardized based on biological activity from urinary extracts, rFSH provides a specific FSH molecule without LH (unless co-administered). This can allow for more tailored treatment regimens and potentially reduce the risk of OHSS in some protocols. However, the LH component in Pergonal is considered beneficial for certain patient populations.
  • Monitoring: Both Pergonal and rFSH require careful monitoring of follicular development via ultrasound and hormone levels (estradiol) to adjust dosage and minimize risks.
• Evolution of Use: Over time, treatment protocols have become more refined, with greater emphasis on individualized dosing based on patient response and risk factors. The introduction of GnRH antagonists has also altered the landscape of controlled ovarian stimulation, often used in conjunction with FSH.

The clinical data supporting Pergonal's efficacy and safety are extensive, but its positioning relative to newer therapies is now informed by comparative studies and the availability of more precise hormonal preparations.

What is the Financial Trajectory and Revenue Generation of Pergonal?

Pergonal's financial trajectory has transitioned from a growth phase driven by its initial market introduction and patent exclusivity to a stabilized, mature revenue stream heavily influenced by generic competition and pricing dynamics.

• Historical Revenue Growth: During its period of patent protection and market exclusivity, Pergonal would have experienced significant revenue growth as it established itself as a leading treatment for infertility. The introduction of the drug addressed a clear unmet medical need.
• Impact of Patent Expiry and Generics: The expiration of key patents for Pergonal led to the entry of generic competitors. This event typically causes a sharp decline in the price of the originator product and a significant erosion of market share. Generic versions, manufactured at lower cost, capture a substantial portion of the market, especially in price-sensitive segments.
• Current Revenue Streams: The revenue generated by Pergonal today is likely comprised of:
  • Brand-Name Sales: Sales of the originator brand, which may still command a premium in certain markets or among specific patient/physician preferences, but likely at significantly reduced volumes.
  • Generic Sales: Revenue from generic versions of Pergonal, which are sold at much lower price points. These sales are volume-driven. The financial benefit accrues to both the originator (if they have a generic arm or licensing agreement) and independent generic manufacturers.
• Pricing Dynamics:
  • Price Erosion: The presence of generics has led to substantial price erosion for Pergonal. This is a standard outcome in the pharmaceutical market once patent exclusivity ends.
  • Value-Based Pricing vs. Cost-Based Pricing: In markets where newer, more advanced therapies are available, Pergonal may be positioned as a more cost-effective, albeit less technologically advanced, option. This can lead to a form of value-based pricing where its cost is compared against the higher cost of alternatives, rather than solely on its intrinsic manufacturing cost.
• Market Volume: While the overall infertility treatment market may be growing, Pergonal's specific market volume has likely stabilized or declined in many developed regions due to competition. However, it may retain a stable or even growing volume in emerging markets where cost is a more significant factor in treatment decisions.
• Profitability: Profitability for the originator brand is likely constrained by lower volumes and potential marketing expenses to defend its niche. For generic manufacturers, profitability is dependent on efficient production and high sales volumes, operating on thinner margins per unit.
• Future Outlook: The financial trajectory for Pergonal is expected to remain stable in its established niche. Significant revenue growth is unlikely. Its financial future is tied to the continued demand for gonadotropin therapy in specific infertility indications and its competitive positioning against both brand-name advanced therapies and other generic gonadotropins.

What are the Regulatory Considerations and Market Access for Pergonal?

Pergonal, like all pharmaceutical products, is subject to stringent regulatory oversight and considerations for market access globally.

• Approvals and Labeling: Pergonal has received marketing authorization from major regulatory agencies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), for its approved indications. These approvals are based on comprehensive reviews of clinical trial data demonstrating safety and efficacy. The drug's labeling reflects its approved uses, dosage, contraindications, warnings, and precautions.
• Post-Market Surveillance: Regulatory agencies require ongoing post-market surveillance to monitor for adverse events and ensure continued safety. Any new safety concerns identified can lead to label changes, prescribing restrictions, or, in rare cases, withdrawal from the market.
• Generic Drug Regulation: For generic versions of Pergonal, regulatory agencies require demonstration of bioequivalence to the reference listed drug (RLD). This means the generic must perform in the body in the same way as the brand-name Pergonal. This process involves specific pharmacokinetic studies.
• Market Access and Reimbursement:
  • Insurance Coverage: The extent to which Pergonal is covered by public and private health insurance plans significantly impacts its accessibility and market penetration. Reimbursement policies can vary widely by country and by individual plan.
  • Formulary Placement: Inclusion on hospital and insurance formularies is critical for market access. This often involves negotiations with payers based on clinical value and cost-effectiveness.
  • Cost-Effectiveness: In a market with multiple treatment options, payers and healthcare systems increasingly scrutinize the cost-effectiveness of drugs. Pergonal's pricing relative to newer therapies influences its formulary placement and market access decisions. As a mature product with generic options, it may be favored in cost-conscious healthcare systems.
  • Prescribing Guidelines: Clinical guidelines issued by professional medical organizations can influence prescribing patterns. If guidelines shift to favor newer therapies, it can impact the demand for Pergonal.
• Global Variations: Regulatory requirements and market access landscapes differ significantly across countries. A drug approved in one region may require separate approvals and market access strategies in others. Emerging markets may have different pricing expectations and reimbursement frameworks.
• Therapeutic Class Re-evaluation: Regulatory bodies may periodically re-evaluate the therapeutic classes of drugs based on new scientific evidence or the availability of superior alternatives. This can influence ongoing approvals and market positioning.

The regulatory environment for Pergonal is mature, with the primary focus now on ensuring the quality and equivalence of generic products and managing its established safety profile within current clinical practice.

What is the Competitive Landscape for Pergonal?

The competitive landscape for Pergonal is multifaceted, encompassing both direct therapeutic alternatives and broader approaches to infertility treatment.

• Direct Competitors (Other Gonadotropins):
  • Recombinant FSH (rFSH): Products like Gonal-f (Merck), Puregon (Organon/Merck), and Bemfola (Gedeon Richter) are key competitors. These are manufactured using recombinant DNA technology, offering a standardized and highly purified FSH. Some rFSH preparations contain only FSH, while others may have added LH or are co-administered with LH. They are often perceived as more advanced and can offer more precise dosing.
  • Urofollitropin (Bravelle): This is another purified urinary FSH, similar in origin to Pergonal but without the LH component. It competes by offering a pure FSH option.
  • Human Menopausal Gonadotropins (hMG) Generics: Beyond the brand-name Pergonal, numerous generic versions of hMG exist, directly competing on price.
• Indirect Competitors (Other Fertility Treatments):
  • Clomiphene Citrate (Clomid, Serophene): An oral medication that stimulates ovulation by affecting estrogen receptors. It is typically a first-line treatment for anovulatory infertility and is significantly less expensive than injectable gonadotropins.
  • Letrozole (Femara): An aromatase inhibitor that can also induce ovulation. It is often used off-label for infertility and competes with clomiphene and gonadotropins.
  • In Vitro Fertilization (IVF) and Intracytoplasmic Sperm Injection (ICSI): These assisted reproductive technologies (ART) are the ultimate competitors for many forms of infertility. While gonadotropins are often used to stimulate follicle development for IVF cycles, ART bypasses the need for natural conception entirely, offering a more direct route for some.
  • GnRH Agonists and Antagonists: These medications are used to control the timing of ovulation and the release of natural hormones, often used in conjunction with FSH during controlled ovarian stimulation protocols for IVF. They represent sophisticated advancements in fertility treatment protocols.
• Key Differentiating Factors in Competition:
  • Cost: Pergonal and its generics offer a lower cost point compared to recombinant products and comprehensive IVF cycles.
  • Hormonal Profile: Pergonal's combination of FSH and LH is considered beneficial for certain patient populations, particularly those with diminished ovarian reserve or certain types of male hypogonadism, where LH plays a critical role.
  • Ease of Use/Administration: While all injectables require administration, advancements in pen devices for rFSH may offer some convenience over traditional vial and syringe methods for some users, although Pergonal can also be available in pre-filled syringes or pen-like devices in some markets.
  • Clinical Outcome Data: Newer therapies often have more contemporary clinical trial data and real-world evidence supporting their use, which can influence physician prescribing habits.

Pergonal's competitive strategy relies on its established efficacy for specific indications, its cost-effectiveness compared to recombinant alternatives, and its established safety profile, particularly in patient groups who may benefit from its combined FSH/LH action.

Key Takeaways

• Pergonal is a mature gonadotropin therapy for infertility with a well-established but niche market position.
• Its patent protection has long expired, leading to significant generic competition and downward price pressure.
• Newer recombinant FSH (rFSH) therapies represent the primary competition, offering standardized hormone profiles and advanced manufacturing.
• Pergonal’s financial trajectory is stable, characterized by mature revenue streams driven by generic sales and a reduced volume of brand-name sales.
• Its key competitive advantage lies in its cost-effectiveness for specific infertility indications and the beneficial FSH/LH hormonal profile for certain patient groups.
• Regulatory oversight focuses on generic equivalence and ongoing safety monitoring, while market access is influenced by reimbursement policies and cost-effectiveness compared to advanced alternatives.

Frequently Asked Questions

1. What is the primary therapeutic benefit of Pergonal's combined FSH and LH content compared to pure FSH preparations? The combined FSH and LH in Pergonal is considered beneficial for women with certain types of anovulation, particularly those with diminished ovarian reserve, as both hormones play critical roles in follicular development and steroidogenesis. For men with hypogonadotropic hypogonadism, LH is crucial for stimulating testosterone production alongside FSH's role in spermatogenesis.
2. How has the availability of generic Pergonal impacted the originator brand's market share and pricing? The entry of generic versions of Pergonal has led to substantial market share erosion for the originator brand and significant price reductions across the product class. The originator brand's sales are now primarily driven by brand loyalty, physician preference in specific niches, or its presence in markets with less price sensitivity.
3. Are there specific patient populations for whom Pergonal remains a preferred treatment option over recombinant FSH therapies? Yes, patients with a documented need for both FSH and LH stimulation, such as those with hypogonadotropic hypogonadism or certain cases of diminished ovarian reserve, may find Pergonal or other hMG preparations preferable. Additionally, in healthcare systems with strict budget constraints, Pergonal's lower cost may make it the preferred option.
4. What are the main regulatory challenges for generic manufacturers of Pergonal? Generic manufacturers must demonstrate bioequivalence to the reference listed drug, establish robust quality control systems for the urine-derived product, and navigate the complex regulatory approval processes in different global markets. Ensuring consistent potency and purity from a biological source material can be a key challenge.
5. Beyond gonadotropins, what other fertility treatments represent indirect competition to Pergonal? Indirect competition includes oral ovulation induction agents like clomiphene citrate and letrozole, which are significantly less expensive and often first-line treatments. Advanced assisted reproductive technologies such as in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) also compete by offering more direct routes to conception for complex infertility cases.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Development. https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/drug-development [2] European Medicines Agency. (n.d.). Medicines. https://www.ema.europa.eu/en/medicines [3] Shrivastava, A. (2018). Gonadotropins in infertility management. Journal of Human Reproductive Sciences, 11(2), 99–105. doi:10.4103/jhrs.jhrs_15_18 [4] Practice Committee of the American Society for Reproductive Medicine. (2016). Preparation of the patient for assisted reproductive technology. Fertility and Sterility, 105(5), 1127–1133. doi:10.1016/j.fertnstert.2016.02.020 [5] Practice Committee of the American Society for Reproductive Medicine. (2017). The Role of GnRH Agonists in Assisted Reproductive Technology. Fertility and Sterility, 108(3), 411-418. doi:10.1016/j.fertnstert.2017.06.010